Brief: Marina Biotech to acquire late-stage program from Turing Pharmaceuticals
03/05/2016 14:00
May 3 (Reuters) -
* Marina Biotech To Acquire Late-Stage program from turing
pharmaceuticals
* Executed a term sheet under which marina intends to
acquire turing's intranasal ketamine program
* Marina is expected to acquire turing's intranasal ketamine
program for approximately 53 million marina common shares
* Further terms of proposed transaction were not disclosed
* Marina will pay to turing up to $95 million in success-
and sales-based milestones plus a mid-single digit royalty on
net sales
Source text for Eikon: ID:nMKWZ8QQKa
Further company coverage: MRNA.PK
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Adhera Therapeutics
See all newsBrief: Adhera Therapeutics Says Melior Pharmaceuticals II Terminates License Deal With Respect To MLR-1019
Brief: Adhera Therapeutics Announces CEO, Senior Management Changes, Plans For Nasdaq Uplist
Brief: Adhera Therapeutics Signs Letter Of Intent With Melior Pharmaceuticals Ii To Acquire A New Class Of Drug For Parkinson’S Disease
Ontario to begin offering second doses of COVID-19 vaccines
Brief: Adhera Therapeutics Inc Determined That Co Would Terminate Its Current Business Operations